Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
  • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
  • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
  • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
  • C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the invention relates generally to anti-cancer compounds and more specifically to glucose conjugates of triptolide and analogs thereof, and methods of treating cancer using such compounds.
• Triptolide is an active component from the traditional Chinese medicinal plant Thunder God Vine. It has been shown to possess anti ⁇ inflammatory, immunosuppressive and anticancer activities, among others. Its molecular target has been identified as the XPB (ERCC3) subunit of the general transcription factor TFIIH. It works by blocking RNAPII transcription initiation and nucleoside excision repair. Triptolide and analogs have been developed as new anticancer and immunosuppressive drugs. Unfortunately, dose ⁇ limiting toxicity and insolubility have been major hurdles for its development as a new drug.
• the present invention is based on the seminal discovery that conjugation of triptolide with glucose to form glucose-triptolide conjugates provides compounds with effective anti- proliferative activity and improved tolerability as compared to naturally occurring triptolide compounds.
• the invention provides a method of treating cancer in a subject comprising administering to the subject an anti-proliferative effective amount of a glucose- triptolide conjugate compound, thereby treating the cancer.
• glucose-triptolide conjugate compounds have the structure of Formula I:
• T&A moiety is triptolide or one of its analogs, and can be selected from compounds 1 to 18:
• L 1 can be selected from–X-Y-Z-, wherein X and Z can individually and independently be a direct bond,–CH 2 -, -C(O)-, -SO-, -SO 2 -, -OPO-, -OPO 2 -, and wherein Y is a direct bond, a substituted or unsubstituted -(C 1 -C 6 )alkyl-, substituted or unsubstituted - (CH 2 ) n O(C 1 -C 6 )alkyl-, substituted or unsubstituted -(CH 2 ) n C(O)(C 1 -C 6 )alkyl-, substituted or unsubstituted -(CH 2 ) n C(O)O(C 1 -C 6 )alkyl-, substituted or unsubstituted -(CH 2 ) n NH(C 1 -C 6 )alkyl-, substituted or unsubsti
• sugar can be selected from compounds 19 to 53:
• the cancer may be one of the following, but not limited to bladder cancer, breast cancer, ovarian cancer, pancreatic cancer, and gastric cancer, cervical cancer, colon cancer, endometrial cancer, head and neck cancer, lung cancer, melanoma, multiple myeloma, leukemia, non-hodgkin's lymphoma, prostate cancer, rectal cancer, malignant melanomas, alimentary/gastrointestinal tract cancer, liver cancer, skin cancer, lymphoma, kidney cancer, muscle cancer, bone cancer, brain cancer, eye or ocular cancer, rectal cancer, colon cancer, cervical cancer, bladder cancer, oral cancer, benign and malignant tumors, stomach cancer, corpus uteri, testicular cancer, renal cancer, throat cancer, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's Sarcoma, Kaposi's Sarcoma, basal cell carcinoma and squamous cell carcinoma, small cell lung cancer, choriocarcinoma, rhabdomyosar
• the cancer is prostate cancer.
• the cancer is metastatic cancer.
• T&A moiety is compound 1 and the sugar is compound 19, 20, 37 or 38.
• L 1 is a direct bond,–COCH 2 CH 2 CO-, or -CH 2 -.
• T&A moiety is compound 1 and the sugar is compound 19.
• the glucose triptolide conjugate compound has a Formula G1- 9.
• the compound is Formula G4.
• Formula G1-9 are illustrated in the structures provided herein.
• the invention also provides a pharmaceutical composition comprising the compounds listed above.
• the method of treatment includes administration intravenously, such as at a dosage of about 0.1 mg/kg to 2 mg/kg per dosage.
• the compound is administered once daily for up to about 4 weeks.
• the method may further include administering a chemotherapeutic compound, for example, prior to, simultaneously with, or following administration of a compound of the invention.
• the method of synthesizing a glucose-triptolide conjugate compound includes synthetic scheme I, II or III. These schemes are provided herein.
• an anti-proliferative effective amount of a glucose-triptolide conjugate compound is administered to a subject in a method to treat possible organ rejection in subjects that have undergone an organ transplant.
• an anti-proliferative effective amount of a glucose-triptolide conjugate compound is administered to a subject in a method to treat autoimmune diseases.
• immune related diseases include but are not limited to: Acute disseminated encephalomyelitis (ADEM), Addison's disease, Ankylosing spondylitis, Antiphospholipid antibody syndrome, Autoimmune hemolytic anemia, Autoimmune hepatitis, Autoimmune inner ear disease, Autoimmune Lymphoproliferative Syndrome (ALPS), Autoimmune polyendocrine/polyglandular syndrome, Autoimmune thrombocytoipenia purpura, Balo disease, Behçet disease, Bullous pemphigoid, Cardiomyopathy, Celiac sprue-dermatitis herpetiformis, Chronic fatigue immune dysfunction syndrome (CFIDS), Chronic inflammatory demyelinating neuropathy, Cicatrical pemphigoid, Coeliac disease, Cold agglutinin disease, CREST syndrome, Crohn’s disease, Cystic fibrosis, Degos disease, Dermatomyositis,
• ADAM Acute disse
• a library of glucose conjugates of triptolide and analogs thereof is used to screen for compounds for treating cancer.
• a library of glucose conjugates of triptolide and analogs thereof is used to screen for compounds for treating possible organ rejection.
• a library of glucose conjugates of triptolide and analogs thereof is used to screen for compounds for treating autoimmune disease.
• Figures 1A-1B (a) The structure of triptolide and glucose conjugated analogs. (b) The octanol-water partition coefficient logP of different analogs using Interactive logP calculator.
• FIG. 2A-2D Effects of G1-5 on HeLa cell proliferation.
• Figure 3 Effects of triptolide and glucose-triptolide conjugate G4 in a metastatic mouse prostate cancer model.
• the injected prostate cancer cells expressed luciferase, which was detected by imaging of live animals.
• the present invention is based on trying to solve the issues of solubility and toxicity associated with triptolide. It was hypothesized that if triptolide could be conjugated to glucose, the two aforementioned problems associated with triptolide could be addressed.
• the glucose ⁇ triptolide conjugates would be preferentially taken up by cancer cells and they should also exhibit much higher water solubility due to the water solubility of glucose moiety.
• cancer or "cancerous growth” means the uncontrolled, abnormal growth of cells and includes within its scope all the well-known diseases that are caused by the uncontrolled and abnormal growth of cells.
• Non-limiting examples of common cancers include bladder cancer, breast cancer, ovarian cancer, pancreatic cancer, and gastric cancer, cervical cancer, colon cancer, endometrial cancer, head and neck cancer, lung cancer, melanoma, multiple myeloma, leukemia (e.g. myeloid, lymphocytic, myelocytic and lymphoblastic leukemias), non-hodgkin's lymphoma, prostate cancer, rectal cancer, and malignant melanomas.
• leukemia e.g. myeloid, lymphocytic, myelocytic and lymphoblastic leukemias
• non-hodgkin's lymphoma prostate cancer, rectal cancer, and malignant melanomas.
• chemotherapeutic agents can be used prior to, simultaneously with or following treatment with invention compounds.
• Illustrative agents include but are not limited to, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof.
• Therapeutic antibodies or other proteins are also envisioned in combination therapies of the invention.
• the in vivo antitumor activity of the glucose-triptolide conjugate G4 was determined using an established metastatic prostate cancer model (Reference 1).
• the luciferase-­ ⁇ expressing prostate cancer line PC3/ML was injected into NOD/SCID/IL2r ⁇ null (NSG) mice through the tail vein.
• NSG NOD/SCID/IL2r ⁇ null mice
• the metastasis of the injected prostate cancer cells into liver, kidney, lung and bone can be monitored in live animals by bioluminescent imaging (BLI). It was shown that this is a reliable model with reproducible liver metastasis and all animals succumb by Week 7 after injection of cells (or Week 4 after initiation of treatments).
• the tolerable treatment dose of triptolide was 0.2 mg/kg and that of G4 to be 1 mg/kg.
• each compound was given once daily by IP at those doses for a total of 4 weeks.
• the surviving animals were continuously monitored upon termination of compound administration.
• mice treated with 11 had lower tumor burden during Weeks 1 and 2 compared with those treated with triptolide.
• both treatment groups showed undetectable tumor cells while all animals in the untreated groups died.
• tumors immediately returned in animals treated with triptolide. But no tumor cells were detectable in those treated with G4 till the end of the experiment, revealing sustained anticancer activity of G4 in vivo.
• glucose triptolide conjugates that are included in the present invention are compounds of Formula I:
• T&A moiety is triptolide or one of its analogs, and can be selected from compounds 1 to 18:
• L 1 can be selected from –X-Y-Z-, wherein X and Z can individually and independently be a direct bond,–CH 2 -, -C(O)-, -SO-, -SO 2 -, -OPO-, -OPO 2 -; Y is a direct bond, a substituted or unsubstituted -(C 1 -C 6 )alkyl-, substituted or unsubstituted -(CH 2 ) n O(C 1 -C 6 )alkyl-, substituted or unsubstituted -(CH 2 ) n C(O)-, substituted or unsubstituted -(CH 2 ) n C(O)(C 1 -C 6 )alkyl-, substituted or unsubstituted -(CH 2 ) n C(O)O(C 1 -C 6 )alkyl-, substituted or unsubstituted -(CH 2 ) n
• sugar can be selected from compounds 19 to 53:

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Biotechnology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Genetics & Genomics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Saccharide Compounds (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=59500284

Family Applications (1)

Country Status (8)

Cited By (2)

Families Citing this family (6)

Citations (3)

Family Cites Families (1)

• 2017
  • 2017-02-03 CN CN201780010159.3A patent/CN108601952B/zh active Active
  • 2017-02-03 EP EP17748283.3A patent/EP3411121B1/en active Active
  • 2017-02-03 JP JP2018540128A patent/JP7042744B2/ja active Active
  • 2017-02-03 AU AU2017214572A patent/AU2017214572A1/en not_active Abandoned
  • 2017-02-03 MX MX2018009406A patent/MX2018009406A/es unknown
  • 2017-02-03 US US16/074,750 patent/US10695319B2/en active Active
  • 2017-02-03 WO PCT/US2017/016527 patent/WO2017136739A1/en not_active Ceased
  • 2017-02-03 CA CA3013619A patent/CA3013619A1/en not_active Abandoned
• 2020
  • 2020-06-11 US US16/899,226 patent/US20200297693A1/en not_active Abandoned

Patent Citations (3)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events